Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world

[1]  F. Martinez,et al.  Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2022, American journal of respiratory and critical care medicine.

[2]  P. Brillet,et al.  Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Respiratory medicine.

[3]  Jonathan H. Chung,et al.  Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[4]  M. Ando,et al.  Acute exacerbations of fibrotic interstitial lung diseases , 2020, Respirology.

[5]  Y. Hara,et al.  Diffuse alveolar hemorrhage complicating acute exacerbation of IPF , 2020, Respiratory medicine case reports.

[6]  T. Johkoh,et al.  Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial. , 2020, American journal of respiratory and critical care medicine.

[7]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[8]  Shinichi Sasaki,et al.  Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis , 2019, Scientific Reports.

[9]  D. Hashimoto,et al.  Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score‐matched analysis , 2019, Respirology.

[10]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[11]  A. Gemma,et al.  Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.

[12]  T. Kishaba.  Evaluation and management of Idiopathic Pulmonary Fibrosis. , 2019, Respiratory investigation.

[13]  F. Sakamaki,et al.  Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases , 2019, Respiratory medicine case reports.

[14]  J. Huggins,et al.  Acute exacerbations of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.

[15]  Takeshi Johkoh,et al.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[16]  A. Gemma,et al.  Japanese guideline for the treatment of idiopathic pulmonary fibrosis. , 2018, Respiratory investigation.

[17]  P. Pelosi,et al.  Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome? , 2018, Critical Care.

[18]  Y. Sugiyama,et al.  Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials , 2017, Respirology.

[19]  H. Collard,et al.  Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis , 2017, European Respiratory Journal.

[20]  H. Tomioka,et al.  Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis , 2017, Respirology case reports.

[21]  D. Lynch,et al.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.

[22]  Y. Nishioka,et al.  Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis , 2015, Core evidence.

[23]  Shandra L. Protzko,et al.  An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. , 2015, American journal of respiratory and critical care medicine.

[24]  M. Bando,et al.  Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. , 2014, American journal of respiratory and critical care medicine.

[25]  N. Katakami,et al.  The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease , 2014, Cancer Chemotherapy and Pharmacology.

[26]  M. Nakazato,et al.  Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis , 2014, Respiratory Research.

[27]  T. Choueiri,et al.  The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients , 2012, Current Oncology Reports.

[28]  R. Kaiser,et al.  A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  R. Kaiser,et al.  Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors , 2010, Molecular Cancer Therapeutics.

[30]  T. Kozuka,et al.  Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[31]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[32]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[33]  Zhen-hua Li.  [The treatment of idiopathic pulmonary fibrosis]. , 2007, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[34]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[35]  A. Millar,et al.  Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm? , 2006, Thorax.

[36]  S. Kudoh,et al.  Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.

[37]  P. Schwartzberg,et al.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.

[38]  Y. Kawabata,et al.  Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. , 1993, Chest.

[39]  O. Dogar.  in with a randomised, double-blind, placebo-controlled phase 3 trial , 2021 .

[40]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[41]  M. L. R. D. Christenson,et al.  An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management , 2012 .